---
document_datetime: 2025-12-29 07:43:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-sandoz.html
document_name: temozolomide-sandoz.html
version: success
processing_time: 0.1054473
conversion_datetime: 2025-12-30 00:47:09.47078
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Temozolomide Sandoz

[RSS](/en/individual-human-medicine.xml/65714)

##### Withdrawn

This medicine's authorisation has been withdrawn

temozolomide Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 September 2022, the European Commission withdrew the marketing authorisation for Temozolomide Sandoz (temozolomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sandoz GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Temozolomide Sandoz was granted marketing authorisation in the EU on 15 March 2010 for treatment of:

- adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment,
- children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. Temozolomide Sandoz is a generic medicine of Temodal. There are other generic medicinal products of Temodal authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Temozolomide Sandoz is updated to indicate that the marketing authorisation is no longer valid.

Temozolomide Sandoz : EPAR - Summary for the public

English (EN) (639.63 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 27/02/2023

[View](/en/documents/overview/temozolomide-sandoz-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-598)

български (BG) (756.99 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/bg/documents/overview/temozolomide-sandoz-epar-summary-public_bg.pdf)

español (ES) (641.51 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/es/documents/overview/temozolomide-sandoz-epar-summary-public_es.pdf)

čeština (CS) (692.81 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/cs/documents/overview/temozolomide-sandoz-epar-summary-public_cs.pdf)

dansk (DA) (639.19 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/da/documents/overview/temozolomide-sandoz-epar-summary-public_da.pdf)

Deutsch (DE) (640.47 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/de/documents/overview/temozolomide-sandoz-epar-summary-public_de.pdf)

eesti keel (ET) (636.55 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/et/documents/overview/temozolomide-sandoz-epar-summary-public_et.pdf)

ελληνικά (EL) (733.02 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/el/documents/overview/temozolomide-sandoz-epar-summary-public_el.pdf)

français (FR) (641.7 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fr/documents/overview/temozolomide-sandoz-epar-summary-public_fr.pdf)

hrvatski (HR) (653.13 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/hr/documents/overview/temozolomide-sandoz-epar-summary-public_hr.pdf)

italiano (IT) (661.4 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/it/documents/overview/temozolomide-sandoz-epar-summary-public_it.pdf)

latviešu valoda (LV) (693.13 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lv/documents/overview/temozolomide-sandoz-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (661.85 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lt/documents/overview/temozolomide-sandoz-epar-summary-public_lt.pdf)

magyar (HU) (728.2 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/hu/documents/overview/temozolomide-sandoz-epar-summary-public_hu.pdf)

Malti (MT) (713.7 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/mt/documents/overview/temozolomide-sandoz-epar-summary-public_mt.pdf)

Nederlands (NL) (641.13 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/nl/documents/overview/temozolomide-sandoz-epar-summary-public_nl.pdf)

polski (PL) (732.89 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pl/documents/overview/temozolomide-sandoz-epar-summary-public_pl.pdf)

português (PT) (639.65 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pt/documents/overview/temozolomide-sandoz-epar-summary-public_pt.pdf)

română (RO) (685.45 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/ro/documents/overview/temozolomide-sandoz-epar-summary-public_ro.pdf)

slovenčina (SK) (693.34 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sk/documents/overview/temozolomide-sandoz-epar-summary-public_sk.pdf)

slovenščina (SL) (700.82 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sl/documents/overview/temozolomide-sandoz-epar-summary-public_sl.pdf)

Suomi (FI) (636.97 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fi/documents/overview/temozolomide-sandoz-epar-summary-public_fi.pdf)

svenska (SV) (637.33 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sv/documents/overview/temozolomide-sandoz-epar-summary-public_sv.pdf)

## Product information

Temozolomide Sandoz : EPAR - Product Information

English (EN) (1.96 MB - PDF)

**First published:** 26/03/2010

**Last updated:** 27/02/2023

[View](/en/documents/product-information/temozolomide-sandoz-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-302)

български (BG) (6.25 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/bg/documents/product-information/temozolomide-sandoz-epar-product-information_bg.pdf)

español (ES) (1.86 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/es/documents/product-information/temozolomide-sandoz-epar-product-information_es.pdf)

čeština (CS) (4.39 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/cs/documents/product-information/temozolomide-sandoz-epar-product-information_cs.pdf)

dansk (DA) (2.01 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/da/documents/product-information/temozolomide-sandoz-epar-product-information_da.pdf)

Deutsch (DE) (1.82 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/de/documents/product-information/temozolomide-sandoz-epar-product-information_de.pdf)

eesti keel (ET) (1.86 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/et/documents/product-information/temozolomide-sandoz-epar-product-information_et.pdf)

ελληνικά (EL) (5.55 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/el/documents/product-information/temozolomide-sandoz-epar-product-information_el.pdf)

français (FR) (1.84 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fr/documents/product-information/temozolomide-sandoz-epar-product-information_fr.pdf)

hrvatski (HR) (1.95 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/hr/documents/product-information/temozolomide-sandoz-epar-product-information_hr.pdf)

íslenska (IS) (1.8 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/is/documents/product-information/temozolomide-sandoz-epar-product-information_is.pdf)

italiano (IT) (1.89 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/it/documents/product-information/temozolomide-sandoz-epar-product-information_it.pdf)

latviešu valoda (LV) (4.37 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lv/documents/product-information/temozolomide-sandoz-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.88 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lt/documents/product-information/temozolomide-sandoz-epar-product-information_lt.pdf)

magyar (HU) (4.61 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/hu/documents/product-information/temozolomide-sandoz-epar-product-information_hu.pdf)

Malti (MT) (4.7 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/mt/documents/product-information/temozolomide-sandoz-epar-product-information_mt.pdf)

Nederlands (NL) (1.83 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/nl/documents/product-information/temozolomide-sandoz-epar-product-information_nl.pdf)

norsk (NO) (1.84 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/no/documents/product-information/temozolomide-sandoz-epar-product-information_no.pdf)

polski (PL) (4.57 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pl/documents/product-information/temozolomide-sandoz-epar-product-information_pl.pdf)

português (PT) (1.75 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pt/documents/product-information/temozolomide-sandoz-epar-product-information_pt.pdf)

română (RO) (1.89 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/ro/documents/product-information/temozolomide-sandoz-epar-product-information_ro.pdf)

slovenčina (SK) (4.24 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sk/documents/product-information/temozolomide-sandoz-epar-product-information_sk.pdf)

slovenščina (SL) (4.06 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sl/documents/product-information/temozolomide-sandoz-epar-product-information_sl.pdf)

Suomi (FI) (1.8 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fi/documents/product-information/temozolomide-sandoz-epar-product-information_fi.pdf)

svenska (SV) (1.72 MB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sv/documents/product-information/temozolomide-sandoz-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0036 15/09/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Temozolomide Sandoz : EPAR - All Authorised presentations

English (EN) (604.77 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 27/02/2023

[View](/en/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-410)

български (BG) (676.01 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/bg/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_bg.pdf)

español (ES) (581.83 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/es/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_es.pdf)

čeština (CS) (656.81 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/cs/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (613.07 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/da/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (598.83 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/de/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (583.24 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/et/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (677.43 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/el/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_el.pdf)

français (FR) (584.01 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fr/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (598.75 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/is/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_is.pdf)

italiano (IT) (598.54 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/it/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (639.96 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lv/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (608.57 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/lt/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (638.07 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/hu/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (657.53 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/mt/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (582.18 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/nl/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (583.77 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/no/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_no.pdf)

polski (PL) (657.52 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pl/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_pl.pdf)

português (PT) (584.44 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/pt/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_pt.pdf)

română (RO) (606.72 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/ro/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (622.5 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sk/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (630.31 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sl/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (599.52 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/fi/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (599.08 KB - PDF)

**First published:**

26/03/2010

**Last updated:**

27/02/2023

[View](/sv/documents/all-authorised-presentations/temozolomide-sandoz-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Temozolomide Sandoz Active substance temozolomide International non-proprietary name (INN) or common name temozolomide Therapeutic area (MeSH) Glioma Anatomical therapeutic chemical (ATC) code L01AX03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.

For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

## Authorisation details

EMA product number EMEA/H/C/001128

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestrasse 10

Opinion adopted 17/09/2009 Marketing authorisation issued 15/03/2010 Withdrawal of marketing authorisation 15/09/2022 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Temozolomide Sandoz : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (751.06 KB - PDF)

**First published:** 01/09/2010

**Last updated:** 27/02/2023

[View](/en/documents/procedural-steps-after/temozolomide-sandoz-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Temozolomide Sandoz : EPAR - Public assessment report

English (EN) (931.03 KB - PDF)

**First published:** 26/03/2010

**Last updated:** 27/02/2023

[View](/en/documents/assessment-report/temozolomide-sandoz-epar-public-assessment-report_en.pdf)

**This page was last updated on** 06/03/2023

## Share this page

[Back to top](#main-content)